ong-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome

Phase 1

• Conditions: Turner Syndrome; MedDRA version: 19.0Level: LLTClassification code 10063020Term: Parsonage-Turner syndromeSystem Organ Class: 100000004852; Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]

• Registration Number: EUCTR2016-001502-42-Outside-EU/EEA
• Lead Sponsor: Eli Lilly and Company Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-06-23
• Last Update Posted: 27 June 2016

Recruitment & Eligibility

• Status: A
• Sex: Female
• Target Recruitment: 88

Inclusion Criteria

Previously randomized in study B9R-US-GDFG; karyotype-proven Turner syndrome
Are the trial subjects under 18? yes
Number of subjects for this age range: 88
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Immediate family members of study site personnel directly affiliated with the study

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified